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At unadjusted analysis, while EF% and the presence of ventrlcu:ar tachy- 
cardia (VT) did not affect 118 prescription, younger age. CHF due lo DCM, 
NYHA class I-II vs III-IV were signllicantly associated with a higher rate of 
pB utlllzallon. 
Multivariate analysis showed that younger age and OCM etiology were 
lndeoendenfly associated wllh more /lB prescriptions (OR 2.11 95%CI 1.6C 
2.7i’and OR-1 35 95% Cl 1.09-l -69). 
Concluslon~: The rale of p0 prescripflons slgnlflcantly increased over the 
last 2 year among oulpatlonls with CHF, Among these pts, the subgroups al 
lower rlak are more likely to bo treated with pS. 
1 1043-55 Atsnolol and Cellprslal do Nat Influence Coronary 
Vaeoreactlve Reeaonae to Acetylchollne In 
Coronary Artery ljlseaee . 
W. Burger1 , C. Hampel. M. Kallenbach, A. Harfmannt , J. Hoffmannl, 
V. Schschlnger, H. Klepzlg. r Deparfment or /nrervenf/ona/ CanYrorcg~ Sf. 
Ciaorg Hcqlfal, leipzlg. Qermnny; Unlvewlfy Hospllal, Fmnklurt, Germany 
Background: Earllor work report potentlated muscarlnlc vaaoconslrlctlva el- 
facts to lnlracoronary acetylchcllno (Ach) after mofoprolol trealmanl In core. 
nary artery dlsaase (CAD). 
Mefhadti: lnlracoronaty Ach (Inlmcomnary concenlrallona: 6.3 x 10 r 
M, 2.6 x 16 s M, 6.3 x 10 ” M) wart glvnn belcra and atlor doubleblInd 
cellprolol (6.30 mglkg Iv.), alenolol (0.15 mgikg Iv.) or placcba In 3 x 12 
patlanta wllh CAD. Syslamlc vascular rosletnnca (SVR, dyn aoc cm s), 
Aoh Induced dlamotor changes (quantltatlvo coronary anglography, mm) of 
proximal (prcx) and dlafal (dlst) se9menla of left anlerlor doscendlng and 
circumflex comnary anorlas nnd Ach Induced change of comnary reslslanoa 
lndox (CR) basod on Oopplor~flow measurements am glvon as mean rl: SD. 
Resub:‘: p -Z 0.05 before vs. after El.blockade. 8: p < 0.05 vs. Cellpmlal. 
Callpmlal Atonolol Placebo 
SW bolero 1091 t43s 1a5ot3os 1723.L215 
nttor 1411 t343' 2101 i: 551'~$ 1709 t214 
Pro~aogmant0 boloto 0.32 * 0.2e -0.42 1: 0.39 --a.30 ,1- c.eo 
IlllOr -0.30 + 0.24 '0.44 -i 0.39 -0.43 * 0.40 
Ok11 segmonta bOlOK7 -0.34 * II.23 -0.38 * 0.37 ,037 IO.21 
nlmr -037 i 0.19 .,0.45 i 0.40 0 41 IO.34 
CAI bolero 0.98 i 0.73 -1.8514.73 1.16 t 129 
lIltor -1.41 t 1.50 -1 92-i 3.74 -1.16 f 1.04 
Conclusions: This confirms the systemic vasodilaory properties of celipro- 
lo1 as compared to atenolol and placebo. However, both b-blockers did not 
influonco Achoinduced coronary vasomotion. 
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Dysfunction: A Double Blind, Placebo Controlled 
Randomized Study 
P.C. Smits. MR. Sasolier, A. Stuunan. J. Kelcfer, P.H. Dunselman, 
A.A. van den 60s. Univetsify Hwpilal Ufrechl anti /gnalius /fospitaf &c/a. 
7'he Netherlands 
Background: Few prospective placebo (PL) controlled pharmacologic studies 
have been performed in patients (pm) with neurocardiogenic dysfunction. 
We investigated the efficacy of metoprolol (MET, 100 mg od) in 26 pts with 
recurrent syncope, suspact of neumcardiogenic origin, and a positive 60Q 
table lilt test (llT) in a single centei. double blind, PL controlled, cross 
over study with treatment periods of 2 weeks. True therapeutic efficacy was 
defined as a negative llT after MET and a positive TTT after PL. true 
therapeutic failure as a positive TTT after MET and a positive ar negative 
Tlf after PL. and a false postlive result was defined as a negative TTT after 
both MET and PL. 
Results: Of the 26 pls randomized. 24 pts completed the study, 14 females, 
10 males. mean age 53 yrs, range 16-75 yrs. True therapeutic efficacy was 
observed in 9/24 pts (36%, Cl. 12-3645, P c 0.01, exact melhod). true 
therapeutic failure in 6/24 pts (33%). In 7/24 pts (29%) there was a false 
posrtive result. No pts had both a positive TTT after MET and a negative TTT 
after PL. 
COncruSion: Beta blockade with MET may reduce neurocardiogenic dys- 
function determined by the results of sequential TTT. but a positive TTT 
does nnt predict the efficacy of beta block..de in pts with neurocardiogenic 
dysfunction. 
I 1043 57 Betablockers and Melatonln Productlon 
P. Lercher, K. Stoschltzky, A. Sakolnlk. M. Schumacher, R. Maler, 
P. Stoschllzky, W. Klein, FACC, P. Llebmann. 8. Ebsr, W. Llndner’ , Dept of 
Inf MedicinelDiv of Cardialogv. University of Graz, Austria; ‘Insf of Analytic 
Chemistry, University of Vienna, Austria 
Background: Sleep disturbances are common side effects of betablockers. In 
order to lnvesllgate the Influence of these drugs on melatonln pmduclon we 
performed a randomized. double-blind, placebo-controlled, cross.over study 
in 15 healthy volunteers. 
Methods: Sublocts recelvod single oral doses of 40 mg (R).pmpanclol, 40 
mg (i?+propanolol, 60 mg (R).atanolol, 60 mg (S).atenolol, 25 mg (R,S).car- 
vadilol and placebo at 8 p.m. Urine was collecled between 10 p.m. and 6 
p.m., and B~aullafox~melatonln (SOM), the msln melabollte cl melatonln, 
which Is almost complelely ellmlnafed In urine, was delemtlnaled by RIA. 
&sulfa: Mean nocturnal excrellon of SOM In urlno after Intake of fhe 
drugs was aa followa: Placebo 26 JIQ; (R).pmpranolol 24 (rg (-7%. n.8.); 
(S).propranolol 5 (19 (-69%, p -Z 0.091); (F+atenolol 27 rrg (+7%, ma.); 
(S)_atenolol 4 rcg (-66%, p .Z 9.01): (R,S)oarvedllol 23 /IQ (-10% ns.). 
Conclusfcn: Our data lndlcate that only Ihe balablocklng (S)+xtantlomam 
of propranolol and atenolol daoraase the nocturnal prcductlon of melalonm 
whareas lho non~betabloaklng (R).enantlamers show no effecl. Theso find. 
lngs mlghl axplaln why betablockers may cause sleep dlslurbances. As a 
consaquenco, admlnlslrallon of malatonln might be a hclplul tool In order to 
avold this slda offcct. Tha mason why carvadllol. which lnhlblts both U- and 
p.adrenocaptom, does not Influence fhe production of melatonln. remains to 
bo delormlnod. 
Randomized, Double-Blind, Placebo-controlled 
Comparatlve Study Between Carvedllol and 
Arotlnolol on the Preventlon of Nitrate Tolerance 
H. Watanabe. M. Kakihana. S. Ohtsuka. Y. Suglshita. K/KU Medical 
Association /+ospifab Mifsukaido: Universify ol Tsukuba. Tsukuba. Japan 
Backgmund: Reduced cGMP production due to Increased supemxide has 
been proposed as a mechanism of nitrate tolerance. Carvedilol combines 
trlp+blcckade (u:p = 1:6) with antloxidant properties. To elucidate the effecl 
of carvedllol on the prevention of nitrate tolerance, we compared the re- 
sponse of forearm blood flow (FBF) and platelet cGMP level to nllmglycerin 
(NTG) between carvedilol and amlinolol (~1 p-blockade without antioxidant 
pmpertlee). 
Melhods: Twenty four patients with untreated hypertension were random- 
ized to receive either carvedilol (5 mg ?Jdice a day [Carvedilol group, n = 6). 
arotinolcl (10 mg twice a day [Arctinolol group, n = 61). or placebo (Placebo 
group, n = 6). Vasodilatory response to NTG was assessed with forearm 
plethysmography by measuring the change in FBF before and 5 mmutes af- 
ter sublingual administration of 0.3 mg NTG. and blood samples were taken 
lo measure platelet cGMP level. Plethysmography and blood sampling were 
obtained serially at baseline (Day 0). 3 days after receiving carvedilol. amtim 
nClol, or placebo (Day 3). and 3 days after application of a 10 mg124 hr NTG 
tape concomitantly with carvedilol, arotinolol. or placebo (Day 6). 
Results: There was no difference in the response of forearm blood flow 
(%FBF) and cGMP (?/ocGMP) to sublingual NTG on Day 0 and Day 3 among 
the three groups. There was no difference in blood pressure and head rate 
on Day 3 and Day 6 between the carvadilol group and the arotinolol group. 
On Day 6. %FBF and %cGMP were significantly lower in the arolinolol group 
(16f7:1219)andtheplacebogmup(15+6;11f6)thanthemonDayO 
and Day 3. but these parameters in the carvedilol group (27 f 12: 31 f 11) 
were similar to them on Day 0 and Day 3. 
Conclusrons: Carvedilol with antioxidant properties may prevent the de- 
velopment of nitrate tolerance dunng continuous therapy with NrG. 
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i 044-29 I Regional Wferences in Patient Characteristics in 
an International Heart Failure Tria! 
B&l. Mass& J.G.F. Cleland. University of California, San Francisco, CA, 
USA 
Few data are available comparing CHF patients (Pts) in different parts of 
the world. Therefore, we compared Pts from North America (NA). Europe 
(Eur) and Australia (Aus) enrolled in ATLAS, a trial evaluating low vs high 
dose lisinopril. in 3164 P!s with NYHA class II-IV CHF and EF < 30%. The 
